|display ongoing studies|
||studied treatment||control treatment||patients||study risk of bias||sample sizes||Results||deaths E||clinical improvement E||death or ventilation E|
COVID-19 severe or critically meta-analysis
|CAP-China (Wang et al.), 2020|
|RCT||remdesivir||placebo||COVID-19 severe or critically||low||158/79||inconclusive|
PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).